Literature DB >> 23564621

Comparison of direct-measured and derived short form six dimensions (SF-6D) health preference values among chronic hepatitis B patients.

Carlos K H Wong1, Elegance T P Lam, Cindy L K Lam.   

Abstract

PURPOSE: The short form six dimensions (SF-6D) are derived from the SF-36 Health Survey with the intention that item data of the latter are often converted to a preference value, which was subsequently used in economic evaluations of interventions. The aim was to compare the equivalence and sensitivity of health preference values derived from the SF-36/SF-12 Health Surveys to that measured directly by the SF-6D for chronic hepatitis B (CHB) patients.
METHODS: This was a secondary analysis of the SF-6D and SF-36 data from a baseline sample of 589 patients with CHB infection with different stages of liver diseases. Degree of agreement (equivalence) between direct-measured and derived SF-6D values was determined using spearman correlation and intra-class correlation. Sensitivity and discriminative power of different SF-6D values were compared by standardized effect size and relative efficiency (RE) statistics.
RESULTS: Significant differences in the direct-measured or derived SF-6D preference values were found between CHB groups. Degree of agreement between SF-6D values was satisfactory. Direct-measured SF-6D was the most efficient, followed by SF-12-derived and the SF-36-derived was the least, based on the standardized effect size and the RE statistics. Sensitivity and discriminative power of direct-measured SF-6D were superior to derived SF-6D among people with different CHB health states.
CONCLUSIONS: Although direct-measured and derived SF-6D preference values had satisfactory sensitivity in discriminating between CHB groups, direct-measured SF-6D is the most sensitive and preferable method of obtaining health preference.

Entities:  

Mesh:

Year:  2013        PMID: 23564621     DOI: 10.1007/s11136-013-0403-z

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  43 in total

1.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

2.  Is the standard SF-12 health survey valid and equivalent for a Chinese population?

Authors:  Cindy L K Lam; Eileen Y Y Tse; Barbara Gandek
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

3.  Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 Health Survey.

Authors:  C L Lam; B Gandek; X S Ren; M S Chan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

4.  Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection.

Authors:  Elegance Ting Pui Lam; Cindy Lo Kuen Lam; Ching Lung Lai; Man Fung Yuen; Daniel Yee Tak Fong
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

5.  Pretransplant variables associated with quality of life in liver transplant recipients.

Authors:  Sammy Saab; Ayman B Ibrahim; Bijal Surti; Francisco Durazo; Steven Han; Hasan Yersiz; Douglas G Farmer; R Mark Ghobrial; Leonard I Goldstein; Myron J Tong; Ronald W Busuttil
Journal:  Liver Int       Date:  2008-07-25       Impact factor: 5.828

6.  A comparison of the performance of the EQ-5D and SF-6D for individuals aged >or= 45 years.

Authors:  Garry R Barton; Tracey H Sach; Anthony J Avery; Claire Jenkinson; Michael Doherty; David K Whynes; Kenneth R Muir
Journal:  Health Econ       Date:  2008-07       Impact factor: 3.046

7.  The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.

Authors:  Adrian R Levy; Kris V Kowdley; Uchenna Iloeje; Eskinder Tafesse; Jayanti Mukherjee; Robert Gish; Natalie Bzowej; Andrew H Briggs
Journal:  Value Health       Date:  2007-12-17       Impact factor: 5.725

8.  Health status versus utilities of patients with end-stage liver disease.

Authors:  Cindy L Bryce; Derek C Angus; JoAnn Switala; Mark S Roberts; Joel Tsevat
Journal:  Qual Life Res       Date:  2004-05       Impact factor: 4.147

9.  Health-related quality of life in chronic hepatitis B patients.

Authors:  Siew Chin Ong; Belinda Mak; Myat Oo Aung; Shu-Chuen Li; Seng-Gee Lim
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index.

Authors:  Amy A Dan; Jillian B Kallman; Ragini Srivastava; Zahra Younoszai; Amy Kim; Zobair M Younossi
Journal:  Liver Transpl       Date:  2008-03       Impact factor: 5.799

View more
  5 in total

1.  EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.

Authors:  Carlos K H Wong; Brian H H Lang; Hill M S Yu; Cindy L K Lam
Journal:  Patient       Date:  2017-08       Impact factor: 3.883

2.  A randomized trial comparing health-related quality-of-life and utility measures between routine fine-needle aspiration cytology (FNAC) and surveillance alone in patients with thyroid incidentaloma measuring 1-2 cm.

Authors:  Carlos K H Wong; Brian H H Lang
Journal:  Endocrine       Date:  2019-11-18       Impact factor: 3.633

3.  Mapping the neck disability index to SF-6D in patients with chronic neck pain.

Authors:  Yongjun Zheng; Kun Tang; Le Ye; Zisheng Ai; Bin Wu
Journal:  Health Qual Life Outcomes       Date:  2016-02-16       Impact factor: 3.186

Review 4.  Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review.

Authors:  Xinyu Qian; Rachel Lee-Yin Tan; Ling-Hsiang Chuang; Nan Luo
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

5.  Increased number of structured diabetes education attendance was not associated with the improvement in patient-reported health-related quality of life: results from Patient Empowerment Programme (PEP).

Authors:  Carlos K H Wong; William C W Wong; Eric Y F Wan; Winnie H T Wong; Frank W K Chan; Cindy L K Lam
Journal:  Health Qual Life Outcomes       Date:  2015-08-12       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.